National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Gestational Trophoblastic Tumors Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 12/05/2007



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Hydatidiform Mole






Placental-Site Gestational Trophoblastic Tumors






Nonmetastatic Gestational Trophoblastic Tumors






Good-Prognosis Metastatic Gestational Trophoblastic Tumors






Poor-Prognosis Metastatic Gestational Trophoblastic Tumors






Recurrent Gestational Trophoblastic Tumors






Get More Information From NCI






Changes to This Summary (12/05/2007)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Treatment Option Overview

Treatment depends on the:

  • Cell type.
  • Stage.
  • Level of serum Beta-human chorionic gonadotrophin (BhCG).
  • Duration of the disease.
  • Specific sites of metastasis.
  • Extent of prior treatment.

Of utmost importance in treating patients with gestational trophoblastic tumors is instituting therapy as quickly as possible and continuing chemotherapy at very close intervals until normal BhCG titers are obtained. The interval between courses should rarely exceed 14 to 21 days depending on the treatment. It is recommended that patients receive one to three courses of chemotherapy after the first normal BhCG titer, depending on the extent of disease. Regardless of stage, if one of the high-risk factors is present, the patient should be treated with combination chemotherapy.

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov